107 related articles for article (PubMed ID: 28478778)
1. Investigation of serum levels of sortilin in response to antidepressant treatment.
Buttenschøn HN; Nielsen M; Glerup S; Mors O
Acta Neuropsychiatr; 2018 Apr; 30(2):111-116. PubMed ID: 28478778
[TBL] [Abstract][Full Text] [Related]
2. Serum sortilin-derived propeptides concentrations are decreased in major depressive disorder patients.
Devader C; Roulot M; Moréno S; Minelli A; Bortolomasi M; Congiu C; Gennarelli M; Borsotto M; Heurteaux C; Mazella J
J Affect Disord; 2017 Jan; 208():443-447. PubMed ID: 27838145
[TBL] [Abstract][Full Text] [Related]
3. Electroconvulsive therapy exerts mainly acute molecular changes in serum of major depressive disorder patients.
Stelzhammer V; Guest PC; Rothermundt M; Sondermann C; Michael N; Schwarz E; Rahmoune H; Bahn S
Eur Neuropsychopharmacol; 2013 Oct; 23(10):1199-207. PubMed ID: 23183131
[TBL] [Abstract][Full Text] [Related]
4. No effect of antidepressant treatment on elevated serum ceruloplasmin level in patients with first-episode depression: a longitudinal study.
Kaya MC; Bez Y; Selek S; Fatih Karababa I; Bulut M; Savaş HA; Celik H; Herken H
Arch Med Res; 2012 May; 43(4):294-7. PubMed ID: 22704847
[TBL] [Abstract][Full Text] [Related]
5. Novel Augmentation Strategies in Major Depression.
Martiny K
Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385173
[TBL] [Abstract][Full Text] [Related]
6. Increased serum levels of sortilin are associated with depression and correlated with BDNF and VEGF.
Buttenschøn HN; Demontis D; Kaas M; Elfving B; Mølgaard S; Gustafsen C; Kaerlev L; Petersen CM; Børglum AD; Mors O; Glerup S
Transl Psychiatry; 2015 Nov; 5(11):e677. PubMed ID: 26556286
[TBL] [Abstract][Full Text] [Related]
7. Anxious distress predicts subsequent treatment outcome and side effects in depressed patients starting antidepressant treatment.
Gaspersz R; Lamers F; Kent JM; Beekman ATF; Smit JH; van Hemert AM; Schoevers RA; Penninx BWJH
J Psychiatr Res; 2017 Jan; 84():41-48. PubMed ID: 27693981
[TBL] [Abstract][Full Text] [Related]
8. Investigation of miR-1202, miR-135a, and miR-16 in Major Depressive Disorder and Antidepressant Response.
Fiori LM; Lopez JP; Richard-Devantoy S; Berlim M; Chachamovich E; Jollant F; Foster J; Rotzinger S; Kennedy SH; Turecki G
Int J Neuropsychopharmacol; 2017 Aug; 20(8):619-623. PubMed ID: 28520926
[TBL] [Abstract][Full Text] [Related]
9. Peripheral vascular endothelial growth factor level is associated with antidepressant treatment response: results of a preliminary study.
Halmai Z; Dome P; Dobos J; Gonda X; Szekely A; Sasvari-Szekely M; Faludi G; Lazary J
J Affect Disord; 2013 Jan; 144(3):269-73. PubMed ID: 23021824
[TBL] [Abstract][Full Text] [Related]
10. S100B Serum Levels Predict Treatment Response in Patients with Melancholic Depression.
Ambrée O; Bergink V; Grosse L; Alferink J; Drexhage HA; Rothermundt M; Arolt V; Birkenhäger TK
Int J Neuropsychopharmacol; 2015 Sep; 19(3):pyv103. PubMed ID: 26364276
[TBL] [Abstract][Full Text] [Related]
11. [Residual symptoms after a treated major depressive disorder: in practice ambulatory observatory carried out of city].
Mouchabac S; Ferreri M; Cabanac F; Bitton M
Encephale; 2003; 29(5):438-44. PubMed ID: 14615693
[TBL] [Abstract][Full Text] [Related]
12. Can people with nonsevere major depression benefit from antidepressant medication?
Stewart JA; Deliyannides DA; Hellerstein DJ; McGrath PJ; Stewart JW
J Clin Psychiatry; 2012 Apr; 73(4):518-25. PubMed ID: 22226407
[TBL] [Abstract][Full Text] [Related]
13. Plasma dehydroepiandrosterone sulfate levels in patients with major depressive disorder correlate with remission during treatment with antidepressants.
Morita T; Senzaki K; Ishihara R; Umeda K; Iwata N; Nagai T; Hida H; Nabeshima T; Yukawa K; Ozaki N; Noda Y
Hum Psychopharmacol; 2014 May; 29(3):280-6. PubMed ID: 24911578
[TBL] [Abstract][Full Text] [Related]
14. Cytokine serum levels remain unchanged during lithium augmentation of antidepressants in major depression.
Ricken R; Busche M; Schlattmann P; Himmerich H; Bopp S; Bschor T; Richter C; Stamm TJ; Heinz A; Hellweg R; Lang UE; Adli M
J Psychiatr Res; 2018 Jan; 96():203-208. PubMed ID: 29101798
[TBL] [Abstract][Full Text] [Related]
15. BDNF, interleukin-6, and salivary cortisol levels in depressed patients treated with desvenlafaxine.
Ninan PT; Shelton RC; Bao W; Guico-Pabia CJ
Prog Neuropsychopharmacol Biol Psychiatry; 2014 Jan; 48():86-91. PubMed ID: 24096053
[TBL] [Abstract][Full Text] [Related]
16. Serum interleukin-6 is a predictive biomarker for ketamine's antidepressant effect in treatment-resistant patients with major depression.
Yang JJ; Wang N; Yang C; Shi JY; Yu HY; Hashimoto K
Biol Psychiatry; 2015 Feb; 77(3):e19-e20. PubMed ID: 25104172
[No Abstract] [Full Text] [Related]
17. Exploring the sortilin related receptor, SorLA, in depression.
Buttenschøn HN; Elfving B; Nielsen M; Skeldal S; Kaas M; Mors O; Glerup S
J Affect Disord; 2018 May; 232():260-267. PubMed ID: 29499509
[TBL] [Abstract][Full Text] [Related]
18. Relationship between baseline severity of depression and antidepressant treatment outcome.
Henkel V; Seemüller F; Obermeier M; Adli M; Bauer M; Kronmüller K; Holsboer F; Brieger P; Laux G; Bender W; Heuser I; Zeiler J; Gaebel W; Mayr A; Riedel M; Möller HJ
Pharmacopsychiatry; 2011 Jan; 44(1):27-32. PubMed ID: 20981642
[TBL] [Abstract][Full Text] [Related]
19. Analysis of potentially predictive factors of efficacy of adjunct extended-release quetiapine fumarate in patients with major depressive disorder.
Bauer M; Thase ME; Liu S; Earley W; Eriksson H
J Psychopharmacol; 2015 May; 29(5):565-74. PubMed ID: 25257148
[TBL] [Abstract][Full Text] [Related]
20. Serotonin 2A receptor clustering in peripheral lymphocytes is altered in major depression and may be a biomarker of therapeutic efficacy.
Rivera-Baltanas T; Olivares JM; Martinez-Villamarin JR; Fenton EY; Kalynchuk LE; Caruncho HJ
J Affect Disord; 2014 Jul; 163():47-55. PubMed ID: 24836087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
